news

Tofacitinib-UV B light therapy combination restores skin colour in vitiligo

47
SHARES

Researchers have successfully applied a novel combination therapy to restore skin colour in patients with vitiligo…

vitiligo

Building on prior research that examined the use of an arthritis medication to treat vitiligo, a team of Yale dermatologists has successfully applied a novel combination therapy — the medication and light — to restore skin colour in patients.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Dr Brett King Associate Professor of Dermatology and his colleagues reported two cases of patients with significant loss of skin colour from vitiligo, a chronic autoimmune disease that destroys skin pigment, leaving white splotches where there had been colour. For Dr King’s patients, standard treatments, such as steroid creams and light treatment, had failed to restore pigmentation.

To address these difficult cases, the research team combined the medication, tofacitinib, with narrowband ultraviolet B light therapy. In recent experiments, King and Dr John Harris, a dermatologist at University of Massachusetts-Worcester, had shown that tofacitinib keeps the immune system from attacking the skin cells that manufacture melanin pigment (colour), and light stimulates pigment-making cells to restore colour to the skin.

After a few months of the combination therapy, there was a remarkable improvement, report the researchers: One patient saw the near-total restoration of skin colour on her face, neck, chest, forearms, and shins. The other patient experienced similar success.

While more research is needed, the study highlights another advance by the Yale team in treating this and other stigmatising skin conditions. “These findings will define the treatment of vitiligo in the future,” Dr King said.

The study has been was published in JAMA Dermatology.

Related topics

Related drugs

Related diseases & conditions

Share via
Share via